Arisaph’s product development mission is to discover and design differentiated “best-in-class” medicines that address unmet medical needs and to develop such medicines internally or through partnerships in an efficient and cost effective manner. By combining our proprietary drug discovery platforms with rational drug design, we can increase the probability of discovering differentiated drug candidates. Our drug discovery platforms can be applied broadly to design highly selective and potent drugs for many targets. Arisaph is actively applying its rational drug design methodologies to seven drug discovery projects.
Pipeline
Arisaph has successfully applied its proprietary specificity profiling and retro-inverso chiral chemistry technology platforms to synthesize several promising lead drug candidates, including a DPP IV inhibitor for Type II diabetes and reverse D-4F, an orally active apo A-I mimetic peptide for the treatment of atherosclerosis. Additionally, Arisaph is developing tumor activated pro-soft drugs for cancer
